Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLorah Perlee, Sara Hamon, Charles Paulding
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.
Claims20
A method for treating a macular degeneration patient having previously been treated with a vascular endothelial growth factor (VEGF) inhibitor for about one year, the method comprising administering aflibercept to the patient in an amount of about 2 mg quarterly after the about one year previous treatment with the VEGF inhibitor when the patient has been determined to have one or more of the single nucleotide polymorphisms rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095.
Dependencies are inferred from the claim text.